Intelligently Targeted Drug Delivery and Enhanced Antitumor Effect by Gelatinase-Responsive Nanoparticles

PLoS ONE

Volumn 8, Issue 7, 2013, Pages

  Li, Rutian ^a   Wu, Wei ^b   Liu, Qin ^a   Wu, Puyuan ^a   Xie, Li ^a   Zhu, Zhenshu ^c   Yang, Mi ^a   Qian, Xiaoping ^a   Ding, Yin ^b   Yu, Lixia ^a   Jiang, Xiqun ^b   Guan, Wenxian ^a   Liu, Baorui ^a  

^a MEDICAL SCHOOL OF NANJING UNIVERSITY   (China)

^b NANJING UNIVERSITY   (China)

^c CHINA PHARMACEUTICAL UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

COPOLYMER; DOCETAXEL; GELATINASE A; GELATINASE B; METHOXY POLY(ETHYLENE GLYCOL) PROLYLVALYLGLYCYLLEUCYLISOLEUCYLGLYCINE POLYCAPROLACTONE NANOPARTICLE; NANOPARTICLE; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; ARTICLE; ATOMIC FORCE MICROSCOPY; CANCER CELL CULTURE; CONTROLLED STUDY; DRUG CYTOTOXICITY; DRUG DELIVERY SYSTEM; EMBRYO; HUMAN; HUMAN CELL; IN VITRO STUDY; LUNG CANCER; MOLECULARLY TARGETED THERAPY; NANOANALYSIS; NANOFABRICATION; NANOPHARMACEUTICS; POLYMERIZATION; PROTEIN EXPRESSION; STOMACH CANCER; TRANSMISSION ELECTRON MICROSCOPY;

AGED; ANTINEOPLASTIC AGENTS; CELL LINE; DRUG CARRIERS; DRUG DELIVERY SYSTEMS; GELATINASES; HUMANS; NANOPARTICLES; NUCLEAR MAGNETIC RESONANCE, BIOMOLECULAR; PARTICLE SIZE; PEPTIDES; POLYMERS; TAXOIDS;

EID: 84880771922     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0069643     Document Type: Article

References (45)

1. Desai N, Trieu V, Yao Z, Louie L, Ci S, et al. (2006) Increased antitumor activity, intratumor paclitaxel concentrations, and endothelial cell transport of cremophor-free, albumin-bound paclitaxel, ABI-007, compared with cremophor-based paclitaxel. Clin Cancer Res 12: 1317-1324.
2. Rosen H, Abribat T, (2005) The rise and rise of drug delivery. Nat Rev Drug Discov 4: 381-385.
3. Maeda H, Bharate G, Daruwalla J, (2009) Polymeric drugs for efficient tumor-targeted drug delivery based on EPR-effect. Eur J Pharm Biopharm 71: 409-419.
4. Huo T, Barth R, Yang W, Nakkula R, Koynova R, et al. (2012) Preparation, Biodistribution and Neurotoxicity of Liposomal Cisplatin following Convection Enhanced Delivery in Normal and F98 Glioma Bearing Rats. PLoS One 7: e48752.
5. Pinhassi R, Assaraf Y, Farber S, Stark M, Ickowicz D, et al. (2010) Arabinogalactan-folic acid-drug conjugate for targeted delivery and target-activated release of anticancer drugs to folate receptor-overexpressing cells. Biomacromolecules 11: 294-303.
6. Lee G, Park K, Kim S, Byun Y, (2007) MMPs-specific PEGylated peptide-DOX conjugate micelles that can contain free doxorubicin. Eur J Pharm Biopharm 67: 646-654.
7. Gullotti E, Yeo Y, (2009) Extracellularly activated nanocarriers: a new paradigm of tumor targeted drug delivery. Mol Pharm 6: 1041-1051.
8. Ganta S, Devalapally H, Shahiwala A, Amiji M, (2009) A review of stimuli-responsive nanocarriers for drug and gene delivery. J Control Release 126: 187-204.
9. Ghadiali J, Stevens M, (2008) Enzyme-Responsive Nanoparticle Systems. Adv Mater 20: 4359-4363.
10. Kang G, Cheon S, Khang G, Song S, (2006) Thermosensitive poly(organophosphazene) hydrogels for a controlled drug delivery. Eur J Pharm Biopharm 63: 340-346.
11. Singh A, Dilnawaz F, Sahoo S, (2011) Long circulating lectin conjugated paclitaxel loaded magnetic nanoparticles: a new theranostic avenue for leukemia therapy. PLoS One 6: e26803.
12. Schmaljohann D, (2006) Thermo- and pH-responsive polymers in drug delivery. Adv Drug Deliv Rev 58: 1655-1670.
13. Mohamad A, Dashevsky A (2006) pH-independent pulsatile drug delivery system based on hard gelatin capsules and coated with aqueous dispersion Aquacoat ECD. Eur J Pharm Biopharm 64: 173-179.
14. Makhlof A, Tozuka Y, Takeuchi H, (2009) pH-Sensitive nanospheres for colon-specific drug delivery in experimentally induced colitis rat model. Eur J Pharm Biopharm 72: 1-8.
15. Li R, Xie L, Zhu Z, Liu Q, Hu Y, et al. (2011) Reversion of pH-induced physiological drug resistance: a novel function of copolymeric nanoparticles. PLoS One 6: e24172.
16. Overall C, Kleifeld O, (2006) Tumor microenvironment- opinion: validating matrix metalloproteinases as drug targets and anti-targets for cancer therapy. Nat Rev Cancer 6: 227-239.
17. Lamparter S, Schoppet M, Christ M, Pankuweit S, Maisch B, (2005) Matrix metalloproteinases and their inhibitors in malignant and autoreactive pericardial effusion. Am J Cardiol 95: 1065-1069.
18. Folgueras A, Pendas A, Sanchez L, Lopez-Otin L, (2004) Matrix metalloproteinases in cancer: from new functions to improved inhibition strategies. Int J Dev Biol 48: 411-424.
19. Coussens L, Fingleton B, Matrisian L, (2002) Matrix metalloproteinase inhibitors and cancer: trials and tribulations. Science 295: 2387-2392.
20. Foda H, Zucker S, (2001) Matrix metalloproteinases in cancer invasion, metastasis and angiogenesis. Drug Discov Today 6: 478-482.
21. Mishra D, Sakamoto J, Thrall M, Baird B, Blackmon S, et al. (2012) Human lung cancer cells grown in an ex vivo 3D lung model produce matrix metalloproteinases not produced in 2D culture. PLoS One 7: e45308.
22. Pellikainen J, Ropponen K, Kataja V, Kellokoski J, Eskelinen M, et al. (2004) Expression of matrix metalloproteinase (MMP)-2 and MMP-9 in breast cancer with a special reference to activator protein-2, HER2, and prognosis. Clin Cancer Res 10: 7621-7628.
23. Liu Z, Li L, Yang Z, Luo W, Li X, et al. (2010) Increased expression of MMP9 is correlated with poor prognosis of nasopharyngeal carcinoma. Bmc Cancer 10: 270.
24. Egeblad M, Werb Z, (2002) New functions for the matrix metalloproteinases in cancer progression. Nat Rev Cancer 2: 161-174.
25. Kuittinen O, Savolainen E, Koistinen P, Turpeenniemi-Hujanen T, (1999) Gelatinase A and B (MMP-2, MMP-9) in leukaemia MMP-2 may indicate a good prognosis in AML. Anticancer Res 19: 4395-4400.
26. Martin M, Matrisian L, (2007) The other side of MMPs: protective roles in tumor progression. Cancer Metastasis Rev 26: 717-724.
27. Li R, Li X, Xie L, Ding D, Hu Y, et al. (2009) Preparation and evaluation of PEG-PCL nanoparticles for local tetradrine delivery. Int J Pharm 379: 158-166.
28. Pasut G, Veronese F, (2009) PEG conjugates in clinical development or use as anticancer agents: an overview. Adv Drug Deliv Rev 61: 1177-1188.
29. Li X, Li R, Qian X, Ding Y, Tu Y, et al. (2008) Superior antitumor efficiency of cisplatin-loaded nanoparticles by intratumoral delivery with decreased tumor metabolism rate. Eur J Pharm Biopharm. 70: 726-734.
30. Turk B, Huang L, Piro E, Cantley E, (2001) Determination of protease cleavage site motifs using mixture-based oriented peptide libraries. Nat Biotechnol 19: 661-667.
31. Egeblad M, Werb Z, (2002) New functions for the matrix metalloproteinases in cancer progression. Nat Rev Cancer 2: 161-174.
32. Liu Q, Li R, Qian H, Yang M, Zhu Z, et al. (2012) Gelatinase-stimuli strategy enhances the tumor delivery and therapeutic efficacy of docetaxel-loaded poly(ethylene glycol)-poly(varepsilon-caprolactone) nanoparticles. Int J Nanomedicine 7: 281-295.
33. Chau Y, Padera R, Dang N, Langer R, (2006) Antitumor efficacy of a novel polymer-peptide-drug conjugate in human tumor xenograft models. Int J Cancer 118: 1519-1526.
34. Scherer R, VanSaun M, McIntyre J, Matrisian L, (2008) Optical imaging of matrix metalloproteinase-7 activity in vivo using a proteolytic nanobeacon. Mol Imaging 7: 118-131.
35. Zhang Y, So M, Rao J, (2006) Protease-modulated cellular uptake of quantum dots. Nano Lett 6: 1988-1992.
36. Jia Y, Shi L, Zhou J, Fu C, Chen L, et al. (2011) Epimorphin promotes human hepatocellular carcinoma invasion and metastasis through activation of focal adhesion kinase/extracellular signal-regulated kinase/matrix metalloproteinase-9 axis. Hepatology 54: 1808-1818.
37. Yang P, Yuan W, He J, Wang J, Yu L, et al. (2009) Overexpression of EphA2, MMP-9, and MVD-CD34 in hepatocellular carcinoma: Implications for tumor progression and prognosis. Hepatol Res 39: 1169-1177.
38. Buergy D, Weber T, Maurer G, Mudduluru G, Medved F, et al. (2009) Urokinase receptor, MMP-1 and MMP-9 are markers to differentiate prognosis, adenoma and carcinoma in thyroid malignancies. Int J Cancer 125: 894-901.
39. Wu W, Wang R, Liu H, Peng J, Huang D, et al. (2009) Prediction of prognosis in gallbladder carcinoma by CD147 and MMP-2 immunohistochemistry. Med Oncol 26: 17-123.
40. Nomura Y, Takasaki K, Tada M, Yoshimoto M, Ishida M, et al. (2007) Pro-MMP-9 is associated with poor prognosis in gastric cancer. Scand J Gastroenterol 42: 1070-1072.
41. Weingarten H, Feder J, (1986) Cleavage site specificity of vertebrate collagenases. Biochem Biophys Res Commun 139: 1184-1187.
42. Kremer R, Best L, Savulescu D, Gavish M, Nagler R, (2010) Pleural fluid analysis of lung cancer vs benign inflammatory disease patients. Br J Cancer 102: 1180-1184.
43. Karakoti A, Das S, Thevuthasan S, Seal S, (2011) PEGylated inorganic nanoparticles. Angew Chem Int Ed Engl 50: 1980-1994.
44. Hatakeyama H, Akita H, Kogure K, Oishi M, Nagasaki Y, et al. (2007) Development of a novel systemic gene delivery system for cancer therapy with a tumor-specific cleavable PEG-lipid. Gene Ther 1: 68-77.
45. Sharma S, Mohanty S, Gupta D, Jassal M, Agrawal AK, et al. (2011) Cellular response of limbal epithelial cells on electrospun poly-ε-caprolactone nanofibrous scaffolds for ocular surface bioengineering: a preliminary in vitro study. Mol Vis. 7: 2898-910.